Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.

You may also be interested in...



Selzentry Patient Population Needs Further Definition, Advisory Panel Urges

Determining the effect of Pfizer's Selzentry (maraviroc) in subpopulations of HIV patients was the theme of recommendations by the Antiviral Drugs Advisory Committee for post-marketing studies Oct. 8

Selzentry Patient Population Needs Further Definition, Advisory Panel Urges

Determining the effect of Pfizer's Selzentry (maraviroc) in subpopulations of HIV patients was the theme of recommendations by the Antiviral Drugs Advisory Committee for post-marketing studies Oct. 8

Selzentry Faces Assay Challenge Even After Advisory Committee Thumbs Up

FDA will wrestle with how to include an unapproved diagnostic test in expanded labeling for Pfizer's HIV drug.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel